PJPascal Joly

Pascal Joly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pascal Joly has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial

    by Pascal Joly, Dedee F Murrell, Yumi Aoyama, Frédéric Caux, Dipankar De, Marilena Flouri, Matthias Goebeler, Chao Ji, Dimitra Kiritsi, Meng Pan, et al.

    Background: Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are rare, chronic, potentially life-threatening, immunoglobulin (Ig)G-mediated, autoimmune skin and/or mucosal blistering diseases. Efgartigimod, a human IgG1 antibody Fc fragment, blocks the neonatal Fc receptor, decreasing IgG recycling and reducing both healthy and pathogenic IgG autoantibody levels. Objectives: To investigate the efficacy, safety and impact of subcutaneous efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in conjunction with prednisone in the treatment of pemphigus. Methods: Adult participants with newly diagnosed or relapsing moderate-to-severe pemphigus were recruited in this phase III, prospective, multicentre, randomised, double-blinded, placebo-controlled study (NCT04598451). Participants were randomised (2 : 1) to weekly subcutaneous efgartigimod PH20 or placebo. Subcutaneous efgartigimod PH20 2000 mg was administered on days 1 and 8, followed by 1000 mg weekly until complete remission on minimal prednisone therapy (CRmin) (≤ 10 mg daily). All participants received concomitant prednisone starting at 0.5 mg kg−1 daily. The primary outcome was the proportion of participants with PV who achieved CRmin by week 30, while receiving minimal prednisone, for ≥ 8 weeks. Pharmacodynamics and safety were also assessed. Results: Overall, 222 participants (PV: n = 190; PF: n = 32) were randomised (subcutaneous efgartigimod PH20: n = 147; placebo: n = 75). The proportions of participants with PV achieving CRmin within 30 weeks were comparable between the subcutaneous efgartigimod PH20 and placebo groups, with no statistically significant difference observed [44/124 (35.5%) vs. 20/66 (30.3%); P = 0.60; odds ratio 1.19 (95% confidence interval 0.60–2.41)]. Total prednisone consumption over time was comparable between groups. Subcutaneous efgartigimod PH20 resulted in rapid reductions from baseline in total IgG and anti–­desmoglein-1 and anti-desmoglein-3 autoantibody levels, but these did not translate to improvements in Pemphigus Disease Area Index scores. The rates of adverse events (AEs) in the subcutaneous efgartigimod PH20 and placebo groups were 89.1% (n = 131/147) and 76.0% (n = 57/75), respectively; most were mild to moderate [serious AEs: 12.2% (n = 18/147) and 13.3% (n = 10/75), respectively]. No deaths occurred. Conclusions: Subcutaneous efgartigimod PH20 in combination with systemic corticosteroids did not demonstrate clinical benefit over systemic corticosteroids alone in patients with moderate-to-severe pemphigus at 30 weeks, but it was well tolerated in this patient population.

  • Open Access

    Expert consensus on oral management in autoimmune bullous diseases, erythema multiforme and SJS / TEN

    by Shalini Nayee, Molly Harte, Saskia Ingen‐Housz‐Oro, Milad Ameri, Sarah Walsh, Pascal Joly, Michael Ardern‐Jones, Vlaho Brailo, Marie‐Charlotte Brueggen, Christopher Bunker, et al.

    Background: Autoimmune bullous diseases ( AIBD ), Stevens‐Johnson syndrome and toxic epidermal necrolysis ( SJS ‐ TEN ) and erythema multiforme ( EM ) often present with clinically similar features in the oral mucosa: classically widespread mucosal erosions or ulceration. Despite this, there are no formalized guidelines for the specific management of the oral manifestations of these conditions. Objectives: We sought to establish an consensus on the management of oral involvement of AIBD , SJS ‐ TEN and EM using the Delphi method. Methods: Participants were sent a survey comprising 62 statements organized into 6 categories: general oral and dental recommendations; disease severity scoring; topical therapies for active oral involvement in AIBD; systemic therapies for active oral involvement in AIBD; additional considerations for inpatient care of AIBD, EM, SJS‐TEN; specific considerations for EM and SJS‐TEN. Participants rated the level of appropriateness of each statement. Results were analysed using the RAND/UCLA Appropriateness Method. Results: 34 experts, primarily Oral Medicine clinicians and Dermatologists, completed the survey. Consensus was achieved for 58 (93.5%) statements after a single round. General recommendations included rigorous oral hygiene and regular dental/periodontal care. Disease‐specific severity scoring was recommended to guide treatment and monitor response. For active oral AIBD, experts recommended moderate‐to‐super potent topical corticosteroids, guided by severity and site of oral disease. For inpatients, supported oral hygiene, regular topical anaesthetics and nutritional support for impaired intake were recommended. For acute EM and SJS‐TEN, recommendations included regular lip care with gentle debridement of haemorrhagic crusts and application of soft paraffin. Conclusions: This Delphi sets out a broad framework for the management of oral involvement in AIBD, SJS‐TEN and EM, to be adapted by a multidisciplinary team, for both acute and long‐term management of these conditions. It may help to standardize the management of oral manifestations of these conditions in future multicentre studies.


  • Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus

    by Maud Maho-Vaillant, Alexis Lefebvre, Marie-Laure Golinski, Sébastien Calbo, Léopoldine Lebourgeois, Marion Carrette, Fabienne Jouen, Chloé Challamel, Nicolas Fazilleau, Carle Paul, et al.

  • Open Access

    Tocilizumab for severe and refractory mucous membrane pemphigoid

    by Billal Tedbirt, Maud Maho‐Vaillant, Julie Gueudry, Marie‐Laure Golinski, Marion Marcaillou, Blanche Bergeret, Guillaume Chambon, Pierre Bouchetemble, Soumeya Bekri, Abdellah Tebani, et al.

    Background: Mucous membrane pemphigoid (MMP) is a rare autoimmune blistering disease involving mucous membranes with a potentially devastating fibrosing course. Laryngotracheal and/or oesophageal involvement may lead to life‐threatening complications, while corneal involvement may lead to blindness. Objectives: To characterize the serum cytokine profile of MMP and to evaluate the efficacy of tocilizumab in nine cases of severe MMP according to the serum levels of IL‐6. Methods: Sera from MMP patients were compared to sex‐ and age‐matched healthy donors (HD) and patients with bullous pemphigoid (BP), using two proteomic assays (Olink and Luminex). The Olink assay included 40 MMP, 40 BP and 40 HD sera, and the Luminex assay included 63 MMP, 31 BP and 24 HD sera. Based on these findings, nine patients with severe and refractory MMP received tocilizumab on a compassionate use basis after failure of standard therapies. Results: Proteomic analyses revealed high serum levels of IL‐6, IL‐8, MIP‐1α/CCL3 and MIP‐1β/CCL4 in MMP compared to BP and HD. Patients with MMP who achieved complete remission during follow‐up had lower baseline serum levels of IL‐6 ( p < 0.0001), IL‐8 ( p = 0.0382), MIP‐1α/CCL3 ( p = 0.0005) and MIP‐1β/CCL4 ( p = 0.0009) than those with persistent disease activity. Nine patients with severe and refractory MMP were treated with tocilizumab. Their mean MMPDAI score decreased from 14.8 ± 6.6 to 4.2 ± 3.2 ( p = 0.009). At the last evaluation, seven patients (78%) were in partial remission, one (11%) in complete remission and one (11%) recently treated achieved control of disease activity. Baseline IL‐6 was elevated in five of eight tested patients; all three with normal IL‐6 levels improved clinically. Four non‐severe adverse events were observed (two neutropenias, one thrombocytopenia, one hepatic cytolysis). Conclusions: Proteomic analyses identified a distinct MMP cytokine profile with increased IL‐6, IL‐8, MIP‐1α/CCL3 and MIP‐1β/CCL4, supporting IL‐6 targeting, with tocilizumab as a potential option in severe refractory MMP.


  • Open Access

    French national protocol for diagnosis and management of pemphigoid gestationis

    by T. Bettuzzi, M. Bruet, F. Jouen, M. Alexandre, C.LE Roux-Villet, F. Caux, C. Lepelletier, E. Tancrède-Bohin, C. Picard-Dahan, F. Lombart, et al.

  • International development of Investigator Global Assessment scores for pemphigus

    by Dédée F. Murrell, Darby Boucher, Maryam Daneshpazhooh, Hamidreza Mahmoudi, Nika Kianfar, Shayan Dasdar, Marc Yale, Anna Wilson, Asli Bilgic, Soner Uzun, et al.

  • Prevalence and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus

    by Billal Tedbirt, Alexandre Lemieux, Maud Maho-Vaillant, Damien Schapman, Leopoldine Lebourgeois, Vivien Hébert, Olivier Boyer, Sébastien Calbo, Pascal Joly, Marie-Laure Golinski

    Anti-muscarinic-acetylcholine-receptor-subtype-M3 (anti-M3AchR) and anti-secretory-pathway-Ca2+/Mn2+-ATPase-isoform-1 (anti-SPCA1) autoantibodies have been suggested as potential targets in pemphigus. However, their role during the course of pemphigus remains poorly characterized. The objective of the study was to determine the frequency, evolution and pathogenicity of anti-SPCA1 and anti-M3AchR autoantibodies in pemphigus. Anti-SPCA1 and anti-M3AchR IgG were detected in almost one-third of sera from patients with pemphigus. We demonstrated their in vitro pathogenic activity, alone or in combination. Anti-SPCA1 and anti-M3AchR autoantibodies were associated with a higher risk of relapse and may help clinicians in patient management.

  • Open Access

    Incidence of P200 pemphigoid: A nationwide study

    by Fabienne Jouen, Marion Carrette, Marie‐Laure Golinski, Maud Maho‐Vaillant, Alexis Lefebvre, André Gillibert, Pascal Joly, Vivien Hébert

    Background: Anti‐p200 pemphigoid (P200) is a rare subepidermal autoimmune blistering disease (AIBD) related to anti‐laminin γ1 autoantibodies (Abs). It has been recently reported that laminin β4 was frequently recognized by sera from patients with P200. Objectives: To evaluate the incidence of P200 in France using a new recombinant anti‐laminin β4 serological assay. Methods: This multicentre retrospective study was conducted in the Immunology Laboratory of the French reference centre for AIBD from January 2018 to March 2023. Sera suspected of corresponding to P200 were tested using the new anti‐LAMB4 cell‐based immunoassay (CBIA) and/or immunoblotting (IB) on dermal extract. The incidence of P200 was then estimated based on its incidence rate relative to those of BP and pemphigus over the same period. Results: 116 patients with sera labelling the dermal side of salt‐split skin by IIF and negative for other junctional AIBD were recorded. Among them, 23 patients' sera had already been tested positive for P200 by dermal IB. Thus, 93 patients' sera were tested with both the anti‐LAMB4 CBIA and IB: 85 were positive with the CBIA (91%) vs. 44 with IB (47%, p < 0.0001). Only two were positive with IB alone. Overall, 110 patients had anti‐p200 Abs. Subsequently, we compared the frequency of serological detection of P200 to that of BP and pemphigus based on data from centres that exhaustively submitted their sera to our reference laboratory. According to the incidence of BP and pemphigus in France (21.7 and 1.85 cases per million inhabitants per year, respectively), the incidence of P200 was estimated to range from 0.23 to 0.83 cases per million inhabitants per year. This corresponds to approximately 16–57 new cases annually in France, which is approximately 2‐ to 4‐fold more frequent than epidermolysis bullosa acquisita . Conclusions: This study shows that P200 may be much more frequent than initially estimated.


  • Open Access

    European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

    by A. Nanda, B. Tedbirt, C. Bodemer, M. C. Bolling, M. El Hachem, M. Nikolić, E. Benton, M. Caproni, D. De, D. Didona, et al.

    Introduction: Autoimmune blistering diseases (AIBDs) in children and adolescents present a major challenge in diagnosis and management because of their rarity and the presence of other differential diagnoses with blistering. They are potentially serious, and timely diagnosis and optimal management can help prevent morbidity related to both the diseases and their treatments. Methods: The Autoimmune Blistering Diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated evidence‐based, expert‐informed clinical guidelines for the diagnosis, treatment and monitoring of paediatric AIBDs. A writing group conducted a systematic review of the available literature on AIBDs in children and adolescents, and since there is limited strong evidence in the literature, recommendations were formulated by consensus over three rounds of structured feedback and revision by the Core Group and Expert Group of the task force (32 voting experts; >75% agreement threshold). Results: Although all AIBDs—including intra‐epidermal and subepidermal blistering disorders—are reported in children, linear IgA dermatosis (LAD) is the most common (42–83%). The diagnostic approach in the paediatric age group does not differ from that in adults. Treatment recommendations are tailored to paediatric patients, taking into account developmental pharmacokinetics, potential adverse effects and the impact of disease and therapy on quality of life. Conclusions: These guidelines provide the first comprehensive, paediatric‐focused framework for the diagnosis and management of AIBDs. Implementing the recommendations should harmonize care, reduce treatment‐related toxicity and improve quality of life for affected children while steering future research towards critical knowledge gaps.